| Description |
1 online resource (113 pages) |
| Contents |
Cover; Contents; Quality and Safety of Medicines; Falsified lamivudine/zidovudine/nevirapine tablets: rapid identification using X-ray fluorescence technique; Instrument used; Testing Method; Tablet testing; Sample Information; Optimization of testing conditions; Results; Discussion; Conclusion; Safety and Efficacy Issues; Rituximab: hepatitis B reactivation; Canada; Oral fluoroquinolones and retinal detachment; Canada; Hydroxyethyl starch solutions: kidney failure; Canada; Ketoconazole: fatal liver injury; United States of America; Olmesartan medoxomil: enteropathy; United States of America |
|
Ado-trastuzumab emtansine: name confusionUnited States of America; Anticholinergics and cognitive impairment; Australia; Diclofenac : new safety advice; European Union; New recommendations for intravenous iron-containing medicines; European Union; Vemurafenib: DRESS syndrome; Singapore; Mefloquine: risk of eye disorders; Singapore; Mefloquine: risk of neurological and psychiatric effects; United States of America; Calcitonin: changes to availability; Canada; Metoclopramide: changes to use; European Union; Glucagon-like-peptide-1 therapies: no immediate concern; European Union |
|
Ergot derivatives: restricted useEuropean Union; Flupirtine-containing medicines: restricted use; European Union; Interim guidelines on bedaquiline for tuberculosis; Regulatory Action and News; Operation Pangea VI: combating sale of unapproved medicines; United States of America; SARA: System for Australian Recall Actions; Australia; Oral ketoconazole: suspension of marketing authorization; European Union; Advanced therapy approved for metastatic prostate cancer; European Union; Dabrafenib approved for metastatic melanoma; European Union; Calcitonin nasal spray: market withdrawal; Canada |
|
Afatinib and companion test approved for late-stage lung cancerUnited States of America; Recent Publications, Information and Events; Priority medicines for Europe and the world; World Health Organization; HIV treatment recommendations; World Health Organization; 18th Model List of Essential Medicines and Model List for Children; World Health Organization; International summit on medicines shortages; USAID Deliver Project: supply chain management; Consultation Documents; The International Pharmacopoeia; Aciclovir; Aciclovir for injection; Aciclovir tablets |
|
Radiopharmaceuticals. General monographRadiopharmaceuticals. Safety considerations; Radiopharmaceuticals. Testing: additional guidance; Radiopharmaceuticals. Methods of analysis: R3, biological methods; Radiopharmaceuticals: specific monograph. Sodiumiodide (131[sup(i)]) solution; Radiopharmaceuticals: specific monograph. Technetium (99M[sup(tc)]) exametazime complex injection; Radiopharmaceuticals: specific monograph. Thallous ([sup(201)]tl) chloride injection; International Nonproprietary Names; Recommended List No. 70; RECOMMENDED International Nonproprietary Names: List 70 |
| Summary |
WHO Drug Information communicates pharmaceutical information that is either developed and issued by WHO or transmitted to WHO by research and regulatory agencies throughout the World. The journal also includes regular presentations of newly proposed and recommended International Nonproprietary Names (INN) for Pharmaceuticals Substances. This volume contains the recommended INN List No. 70 |
| Notes |
Dénominations communes internationales des Substances pharmaceutiques (DCI) |
|
Print version record |
| Subject |
Drugs -- Standards -- Periodicals
|
|
Pharmaceutical industry -- Periodicals
|
|
Drugs -- Standards
|
|
Pharmaceutical industry
|
| Genre/Form |
Periodicals
|
| Form |
Electronic book
|
| ISBN |
9789240692183 |
|
9240692185 |
|
